Pregled bibliografske jedinice broj: 50153
Is PPI-triple Therapy of Greater Efficacy in Peptic Ulcer than in Non-Ulcer Dyspeptic Patients?
Is PPI-triple Therapy of Greater Efficacy in Peptic Ulcer than in Non-Ulcer Dyspeptic Patients? // Gut2000 ; 47(Suppl 1)
London : Delhi: British Medical Journal, 2000. (predavanje, međunarodna recenzija, sažetak, znanstveni)
CROSBI ID: 50153 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Is PPI-triple Therapy of Greater Efficacy in Peptic Ulcer than in Non-Ulcer Dyspeptic Patients?
Autori
Katičić, Miroslava ; Prskalo, Marija ; Tićak, Mirjana ; Šabarić, Branka ; Škurla, Bruno ; Filipec, Tajana ; Presečki, Vladimir ; Čolić-Cvrlje, Vesna ; Dominis, Mara ; Papa, Branko ; Naumovski-Mihalić, Slavica ; Kalenić, Smilja ; Plečko, Vanda ; Džebro, Sonja
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni
Izvornik
Gut2000 ; 47(Suppl 1)
/ - London : Delhi : British Medical Journal, 2000
Skup
XIIIth International Workshop on Gastroduodenal pathology and Helicobacter Pylori
Mjesto i datum
Rim, Italija, 11.10.2000. - 14.10.2000
Vrsta sudjelovanja
Predavanje
Vrsta recenzije
Međunarodna recenzija
Ključne riječi
Helicobacter pylori; terapija; ulkus; neulkusna dispepsija;
(Helicobacter pylori; therapy; ulcus; non-ulcer dyspepsia)
Sažetak
Aim: The aim of this study was to examine the possible difference in efficacy of PPI-based triple therapy among Hp+ patients with duodenal/gastric (DU/GU) ulcers and nonulcer dyspepsia (NUD). Methods: 857 Hp+ consecutive patients with DU (n=481, 266m/215F, mean age 48.6), GU (n=230, 108M/122F, mean age 59.7) and NUD (n=146, 86M/60F, mean age 52.9) treated with 7-days PPI plus amoxycillin and either azithromicyn or metronidazole. Seven biopsies from antrum and corpus for rapid urease test (1), histology (4), and culture (2) were taken during first endoscopy and at least 4 weeks after the end of antibiotics treatment. Hp was considered eradicated when all tests were negative. Results: Baseline characteristics of three groups were not statistically different for sex, age and prescribed therapy. Pre-treatment metronidazole resistance was 33.9 in DU group, 36.3 in GU group, and 43.8 in NUD group ; azithromycin resistance was 7.7, 9.8 and 10.0, respectively (NS). Per protocol eradication was achieved in 387/481 (80%, 95%CI:68-90%) in DU group, 173/230 (75%, 65-84%) in GU group, and 96/146 (65%, 56-77%) in NUD group. Complete clinical improvement was achieved in 72%, 73% and 65%, respectively. Conclusion: The efficacy of eradication therapy as well as clinical improvement was significantly lower in NUD group, especially compared to patients with DU. The mechanism of this difference remains to be explored.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti, Javno zdravstvo i zdravstvena zaštita
POVEZANOST RADA
Ustanove:
Medicinski fakultet, Zagreb
Profili:
Vanda Plečko
(autor)
Vesna Čolić-Cvrlje
(autor)
Smilja Kalenić
(autor)
Branko Papa
(autor)
Mirjana Tićak
(autor)
Marija Prskalo
(autor)
Slavica Naumovski-Mihalić
(autor)
Miroslava Katičić
(autor)
Tajana Filipec Kanižaj
(autor)
Branka Šabarić
(autor)
Vladimir Presečki
(autor)